ATE186640T1 - Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung neurogenerativer erkrankungen - Google Patents

Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung neurogenerativer erkrankungen

Info

Publication number
ATE186640T1
ATE186640T1 AT94921698T AT94921698T ATE186640T1 AT E186640 T1 ATE186640 T1 AT E186640T1 AT 94921698 T AT94921698 T AT 94921698T AT 94921698 T AT94921698 T AT 94921698T AT E186640 T1 ATE186640 T1 AT E186640T1
Authority
AT
Austria
Prior art keywords
efaroxan
derivatives
treatment
production
medicinal product
Prior art date
Application number
AT94921698T
Other languages
English (en)
Inventor
Francis Colpaert
Michael Briley
Thierry Imbert
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Application granted granted Critical
Publication of ATE186640T1 publication Critical patent/ATE186640T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
AT94921698T 1993-07-09 1994-07-07 Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung neurogenerativer erkrankungen ATE186640T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9308497A FR2707166B1 (fr) 1993-07-09 1993-07-09 Utilisation de l'efaroxan et de ses dérivés pour la fabrication de médicaments destinés au traitement de maladies neurodégénératives et leur progression .

Publications (1)

Publication Number Publication Date
ATE186640T1 true ATE186640T1 (de) 1999-12-15

Family

ID=9449128

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94921698T ATE186640T1 (de) 1993-07-09 1994-07-07 Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung neurogenerativer erkrankungen

Country Status (14)

Country Link
US (1) US5661172A (de)
EP (1) EP0707477B1 (de)
JP (1) JP3494651B2 (de)
AT (1) ATE186640T1 (de)
AU (1) AU688346B2 (de)
CA (1) CA2166781A1 (de)
DE (1) DE69421705T2 (de)
DK (1) DK0707477T3 (de)
ES (1) ES2140544T3 (de)
FR (1) FR2707166B1 (de)
GR (1) GR3032531T3 (de)
NZ (1) NZ268914A (de)
PT (1) PT707477E (de)
WO (1) WO1995001791A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2752163B1 (fr) * 1996-08-12 1998-10-30 Pf Medicament Utilisation de l'efaroxan pour la fabricaton de medicament destine au traitement de la maladie de huntington
TWI251813B (en) * 2001-11-09 2006-03-21 Via Tech Inc Method for protecting phase lock loop in optical data-reading system
US8188126B2 (en) * 2002-05-16 2012-05-29 Pierre Fabre Medicament Imidazolic compounds and use thereof as alpha-2 adrenergic receptors
US9107917B2 (en) * 2005-05-13 2015-08-18 The Feinstein Institute For Medical Research Treatment of sepsis and inflammation with alpha2A adrenergic antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ201219A (en) 1981-07-28 1984-10-19 Reckitt & Colmann Prod Ltd Dihydrobenzofuranyl-2-imidazolines and pharmaceutical compositions
US4855308A (en) * 1987-12-04 1989-08-08 Warner-Lambert Company Method of treating senile cognitive decline with N'-substituted aminopyridine adrenergic agents
US4855385A (en) * 1988-06-22 1989-08-08 The Dow Chemical Company Monocarboxylic acid derivatives of aliphatic based epoxy resins
FR2669030B1 (fr) * 1990-11-14 1992-12-31 Adir Nouveaux derives d'imidazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.

Also Published As

Publication number Publication date
JPH08512305A (ja) 1996-12-24
WO1995001791A2 (fr) 1995-01-19
ES2140544T3 (es) 2000-03-01
DE69421705D1 (de) 1999-12-23
EP0707477A1 (de) 1996-04-24
FR2707166A1 (fr) 1995-01-13
JP3494651B2 (ja) 2004-02-09
GR3032531T3 (en) 2000-05-31
WO1995001791A3 (fr) 1995-03-09
NZ268914A (en) 1999-06-29
AU688346B2 (en) 1998-03-12
DE69421705T2 (de) 2000-06-29
EP0707477B1 (de) 1999-11-17
DK0707477T3 (da) 2000-05-15
AU7230894A (en) 1995-02-06
CA2166781A1 (fr) 1995-01-19
PT707477E (pt) 2000-04-28
FR2707166B1 (fr) 1995-09-29
US5661172A (en) 1997-08-26

Similar Documents

Publication Publication Date Title
DE69636343D1 (de) Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen
ATE144420T1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
ATE205086T1 (de) Verwendung von dem chelatbildner clioquinol zur herstellung eines arzneimittelszur behandlung von alzheimerschen krankheit
DE69515038D1 (de) Verwendung von raloxifen und dessen analogen zur herstellung eines medikaments zur behandlung viraler erkrankungen
DE69713620D1 (de) Verwendung von arachidonsäure und/oder docohexaensäure zur herstellung eines arzneimittels zur behandlung von dyspraxia
DE59508961D1 (de) Verwendung von weihrauch zur behandlung der alzheimer-krankheit
DE60221283D1 (de) Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden
ATE252897T1 (de) Verwendung von p-aminophenolderivaten zur herstellung von pharmazeutischen zusammensetzungen zur behandlung von neurodegenerativen erkrankungen
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
DE69501359D1 (de) Verwendung von Phosphatdiestern zur Behandlung von Erkrankungen der Retina
ATE191342T1 (de) Verwendung von riluzol zur behandlung mitochondrialer erkrankungen
ATE186640T1 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung neurogenerativer erkrankungen
ATE194076T1 (de) Verwendung von n,s-diacetylcystein-ethylester (dacee) zur herstellung eines medikaments zur behandlung viraler erkrankungen
DE69424415D1 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit
ATE143946T1 (de) N-acylpyrrolidine und arzneimittel zur behandlung oder prophylaxe von mit ckk und gastrin in zusammenhang stehenden krankheiten
ATE189385T1 (de) Verwendung von benzonaphtalene-derivaten zur herstellung eines arzneimittels zur behandlung von krankheiten des nervensystems
ATE492285T1 (de) Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis
ATE331523T1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
ATE263565T1 (de) Verwendung von 8,9-dehydroestron zur herstellung eines arzneimittels zur behandlung von durch freie radikale verursachte krankheiten
DE69610045D1 (de) Verwendung eines Rohpflanzenextraktes zur Herstellung eines Arzneimittels zur Behandlung von HIV-Infektionen
GR3031544T3 (en) New derivatives of pyridine or pyridazine, process for production thereof and medicaments containing these compounds
ATE173921T1 (de) Verwendung von deoxyspergualin zur herstellung eines arzneimittels zur behandlung von entzündlich-hyperreaktiven erkrankungen
ATE230608T1 (de) Verwendung von bradykinin-antagonisten zur herstellung von arzneimitteln zur behandlung und prävention der alzheimer'schen krankheit
ATE168697T1 (de) Pyrrolidinderivate zur behandlung von cck und gastrin-abhängigen erkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee